Meribank Biotech has signed a letter of intent with Ahead Medicine and Apexcella Biomedical, focusing on optimizing allogeneic natural killer (NK) cell manufacturing and building an AI-based immune cell detection platform. The collaboration aims to strengthen the technical foundation for mass production and standardization of NK cell therapies, expanding clinical applications of umbilical cord blood immune cells.